白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2011年
3期
185-187
,共3页
硼替佐米%淋巴瘤,套细胞%分子作用机制
硼替佐米%淋巴瘤,套細胞%分子作用機製
붕체좌미%림파류,투세포%분자작용궤제
Bortezomib%Lymphoma,mantle-cell%Molecular mechanism of action
套细胞淋巴瘤(MCL)是生存期最短的非霍奇金淋巴瘤(NHL),目前尚不能根治.硼替佐米是第一个用于治疗血液系统恶性肿瘤的蛋白酶体抑制剂,主要用于多发性骨髓瘤(MM)及复发难治性MCL的治疗.探讨硼替佐米治疗MCL的相关机制,其中包括调节细胞周期、影响细胞凋亡、干扰MCL的微环境以及与其他抗肿瘤药物的协同作用等,有助于未来合理应用硼替佐米治疗MCL.
套細胞淋巴瘤(MCL)是生存期最短的非霍奇金淋巴瘤(NHL),目前尚不能根治.硼替佐米是第一箇用于治療血液繫統噁性腫瘤的蛋白酶體抑製劑,主要用于多髮性骨髓瘤(MM)及複髮難治性MCL的治療.探討硼替佐米治療MCL的相關機製,其中包括調節細胞週期、影響細胞凋亡、榦擾MCL的微環境以及與其他抗腫瘤藥物的協同作用等,有助于未來閤理應用硼替佐米治療MCL.
투세포림파류(MCL)시생존기최단적비곽기금림파류(NHL),목전상불능근치.붕체좌미시제일개용우치료혈액계통악성종류적단백매체억제제,주요용우다발성골수류(MM)급복발난치성MCL적치료.탐토붕체좌미치료MCL적상관궤제,기중포괄조절세포주기、영향세포조망、간우MCL적미배경이급여기타항종류약물적협동작용등,유조우미래합리응용붕체좌미치료MCL.
Mantle cell lymphoma is a distinct subtype of non-Hodgkin lymphoma (NHL) that remains incurable with the shortest survival time. Bortezomib is the first proteasome inhibitor used for the treatment of hematological malignant diseases, such as multiple myeloma and relapse or refractory mantle cell lymphoma (MCL). Investing the mechanism of bortezomib for MCL, including modulation of cell cycle, the influence of cell apoptosis, the disturbance of the MCL microenvironment and the cooperative action with other antineoplastic drugs, is helpful to make the treatment strategy for MCL.
